Thursday, June 13, 2024

Despite doubts, Mexico to administer hydroxychloroquine to 20,000

The federal Health Ministry will use the anti-malaria drug hydroxychloroquine to treat 20,000 Covid-19 outpatients despite doubts about its efficacy and the risk of it causing an irregular heartbeat and even death.

The director of the National Institute of Medical Sciences and Nutrition told the newspaper Milenio that the health regulatory agency Cofepris has authorized the administration of the drug to patients recovering from Covid-19 in their homes.

José Sifuentes acknowledged that clinical trials have shown that high doses of hydroxychloroquine for a prolonged period of time can cause a range of side effects in Covid-19 patients but emphasized that the drug has been shown to reduce generalized inflammation in people with the disease.

In that context, he stressed that outpatients will be given only low to medium doses for a maximum of seven days starting in the early phase of their illness.

Sifuentes said that all patients receiving treatment with the drug will be closely monitored, explaining that the “careful follow-up” will occur at people’s homes and via telephone and video calls.

He said that 130,000 doses of hydroxychloroquine donated by the Swiss healthcare company Novartis will be distributed to national health institutes, regional hospitals and specialty hospitals, among other facilities. The use of the drug among ambulatory Covid-19 patients will commence next week.

The announcement of the plan came just two days after the World Health Organization (WHO) reiterated that the drug should only be used in closely-monitored clinical trials due to the potential side effects.

Michael Ryan, executive director of the WHO health emergencies program, said that hydroxychloroquine and the similar drug chloroquine have “yet to be found effective in the treatment of Covid-19” or to prevent the disease.

The medical journal The Lancet published a study on Friday that said that there were no benefits to treating Covid-19 with either drug and that their use actually increases the risk of dying for coronavirus patients.

In a study of 96,000 coronavirus patients, 18% treated with hydroxychloroquine and 16.4% of those treated with chloroquine died. For patients in a control group, the death rate was 9%.

Deputy Health Minister Hugo López-Gatell, Mexico’s coronavirus point man, is among a large number of medical professionals who have warned against taking hydroxychloroquine as a preventative measure against Covid-19.

But United States President Donald Trump, who has repeatedly promoted the drug as a Covid-19 treatment, was not dissuaded from using it to try to stave off Covid-19, the disease caused by the new coronavirus.

“A lot of good things have come out about the hydroxy,  you’d be surprised about how many people are taking it … before you catch it. …  I happen to be taking it …” he told reporters on Monday.

“Couple of weeks ago, I started taking it because I think it’s good, I’ve heard a lot of good stories. And if it’s not good I’m not going to get hurt by it. It’s been around for 40 years for malaria, for lupus, for other things. I take it, frontline workers take it, a lot of doctors take it …” Trump said.

Source: Milenio (sp) 

Have something to say? Paid Subscribers get all access to make & read comments.
Refugees displaced by an armed attack on their Chiapas town stand in the bleachers of a open air sports court and look at proceedings below through a protective wire fence

Over 4,000 residents flee Chiapas town following armed attack

Thousands in the Chiapas town who fled a June 4 armed attack by a criminal group refuse to go home until authorities can ensure their safety.
An endangered vaquita swimming in the ocean

May vaquita porpoise survey finds fewer specimens than in 2023

The survey, which takes place annually in Mexico’s Upper Gulf of California, recorded the lowest-ever number of individual vaquitas.
Man in uniform and hard hat spraying auditorium seats for mosquitos, surrounded by pesticide fumes.

Study shows dengue cases in Mexico primed for widespread expansion

As dengue cases in Mexico continue to rise in 2024, a new study predicts that the mosquito-borne virus will affect 81% of Mexico by 2039.